Core Viewpoint - 康方生物's five approved drugs have been successfully included in the latest version of the National Medical Insurance Drug List (2025) in China, which will be implemented from January 1, 2026 [1][2][3] Group 1: Drug Approvals and Indications - 开坦尼® (卡度尼利, PD-1/CTLA-4) has renewed its original indication for recurrent or metastatic cervical cancer and added new indications for first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer, as well as first-line treatment for persistent, recurrent, or metastatic cervical cancer [1] - 依达方® (依沃西, PD-1/VEGF) has renewed its original indication for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after progression on EGFRTKI treatment and added a new indication for first-line treatment of PD-L1 positive (TPS≥1%) locally advanced or metastatic NSCLC [1] - 安尼可® (派安普利, PD-1) is included for the treatment of second-line and above classical Hodgkin lymphoma, first-line locally advanced or metastatic squamous NSCLC, second-line or above nasopharyngeal carcinoma, and first-line nasopharyngeal carcinoma [2] - 伊喜宁® (伊努西, PCSK9) is included for the treatment of primary hypercholesterolemia and mixed hyperlipidemia, as well as heterozygous familial hypercholesterolemia [2] - 爱达罗® (依若奇, IL-12/IL-23) is included for the treatment of moderate to severe plaque psoriasis [3] Group 2: Company Commitment and Future Plans - The company is dedicated to providing more innovative and best-in-class treatment options for patients and aims to continuously improve patient accessibility and affordability [3] - The company plans to deepen its focus in various disease areas and advance more innovative drugs and new indications into the National Medical Insurance Drug List to benefit more patients [3]

Core Viewpoint - The stock of ZhiJie AnKang-B (02617) has surged over 10%, reaching a new high of 78 HKD, driven by its inclusion in the Hong Kong Stock Connect program and the progress of its clinical trials for its core product, Tinengotinib [1] Group 1: Stock Performance - ZhiJie AnKang-B's stock increased by 10.14%, trading at 69.5 HKD with a transaction volume of 32.81 million HKD [1] Group 2: Market Announcement - The Shanghai Stock Exchange and Shenzhen Stock Exchange announced that ZhiJie AnKang has been added to the Hong Kong Stock Connect eligible list, effective from September 8 [1] Group 3: Clinical Development - ZhiJie AnKang has completed the first patient dosing in a Phase II clinical study for its core product, Tinengotinib, in combination with Canfite BioPharma's treatments for advanced hepatocellular carcinoma [1]